Updated 02:01 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,876.40 -0.25% CL 88.33 -0.26% BTC 64,613.34 +0.76%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,876 −0.25% BTC $64,613 +0.76% VIX 19.30 +3.21% latest tape · as of 02:01 UTC
The Screen

The Carlyle Group Inc. 4.625% Subordinated Notes due 2061

CGABL · Nasdaq · USD

FAIL · Does not pass the screen
14.17 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price14.17 USD at the 13 Nov 2026 close
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Distribution ?
Screened · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price14.17 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-25Read Distribution15.60-9.2% to today ✓Markup gives way to Distribution first Distribution read since October
2026-10-18Read Markup15.60-9.2% to today Distribution gives way to Markup while volume is distributing
2026-10-11Read Distribution15.77-10.1% to today ✓Markdown gives way to Distribution
2026-07-02Read Markdown16.16-12.3% to today ✓First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 holds its Distribution at $14.17. Elevated stress, defensive posture warranted, held for 11 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateElevated stress, defensive posture warranted, held for 11 days
Price at the screen$14.17
ValuationN/A trailing · N/A forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens, Shown in Full

Does not pass. Interest/revenue 12.1%

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load Excluded Below 33% Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash Excluded Below 33% Interest-bearing cash and securities are of assets, above the one-third limit. Fail
Receivables Excluded Below 49% Money owed to the company is of assets, above the 49% limit. Fail
Revenue purity 12.08% Below 5% 12.1% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 does not pass the ethical screen. The binding factor is interest/revenue 12.1%.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

2026-10-25 Does not pass

The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 does not pass the ethical screen. The binding factor is interest/revenue 12.1%.

2026-10-04

The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24

We do not yet have the financial statements needed to run the debt, cash, receivables and income screens for The Carlyle Group Inc. 4.625% Subordinated Notes due 2061, so it is not scored yet.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

Follow this verdict

Get an email when CGABL's ethical verdict changes

Today CGABL does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

Where & How to Trade

CGABL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-05 Distribution $15.40 -1.3% Entry 10

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-10-25 Distribution · changed $15.60 +0.0% Entry 9

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-10-18 Markup · changed $15.60 -1.1% Entry 8

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-10-11 Distribution · changed $15.77 +0.0% Entry 7

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-10-02 Markdown $15.77 -2.4% Entry 6

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-08-25 Markdown $16.16 +0.0% Entry 5

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-07-24 Markdown $16.16 +0.0% Entry 4

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-07-18 Markdown $16.16 +0.0% Entry 3

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-07-03 Markdown $16.16 +0.0% Entry 2

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markdown $16.16 Entry 1

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $17.11 -5.9% · $941 -5.9%
2 months $17.13 -6.0% $0.29 $957 -4.3%
3 months $17.11 -5.9% $0.29 $958 -4.2%
6 months $17.13 -6.0% $0.58 $974 -2.6%
1 year $15.86 +1.5% $1.16 $1,088 +8.8%
2 years $15.70 +2.5% $2.31 $1,172 +17.2%
3 years $15.74 +2.3% $3.47 $1,243 +24.3%
5 years $18.74 -14.1% $5.79 $1,168 +16.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CGABL does next, these words stay.

The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 · CGABL · Distribution · $14.17
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.